Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial-Reference-Cited by-同舟云学术

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial

Published:2016-01-05 Issue:1 Volume:11 Page:e0144917
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Cooper David A.,Cordery Damien V.,Zajdenverg Roberto,Ruxrungtham Kiat,Arastéh Keikawus,Bergmann Frank,Neto José L. de Andrade,Scherer Joseph,Chaves Ricardo L.,Robinson Patrick,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference39 articles.

1. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial;P Cahn;Clin Infect Dis,2006

2. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials;CB Hicks;Lancet,2006

3. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults;S Staszewski;New England Journal of Medicine,1999

4. Atiretroviral treatment of adult HIV infection 2014 –Recommendations of the International Antiviral society–USA Panel;HF Günthard;Journal Amer Medical Assoc,2014

5. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study;B Clotet;Lancet,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conformational dynamics of a multidomain protein by neutron scattering and computational analysis;Biophysical Journal;2021-08

2. Multidomain drug delivery systems of β-casein micelles for the local oral co-administration of antiretroviral combinations;Journal of Colloid and Interface Science;2021-06

3. A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria;Toxicology Research;2021-02-15

4. Is the Deductive Falsification Approach a Better Basis for Clinical Trial Appraisal?;Reviews on Recent Clinical Trials;2019-08-21

5. Adverse effects of chronic treatment with the Main subclasses of highly active antiretroviral therapy: a systematic review;HIV Medicine;2019-04-22